FLCN and neoplasm: To determine whether sirolimus can also exert suppression on human FLCN-deficient tumor growth, we developed a xenograft tumor mouse model for testing by inoculating human FLCN-deficient UOK 257-1 cells that were isolated from the original UOK 257 line [35].